CCND1 and neoplasm: Furthermore, in the MDA-MB-468 tumor xenograft mouse model, we demonstrated the synergistic tumor growth inhibition effect of ruxolitinib and calcitriol combination treatment in a manner consistent with the findings of in vitro experiments, including the alteration of c-PARP, cyclin D1, and c-Myc expression without significant drug toxicity.